Actively Recruiting
Haemoadsorption During Heart Transplantation
Led by Medical University of Vienna · Updated on 2025-05-09
40
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated
CONDITIONS
Official Title
Haemoadsorption During Heart Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients undergoing heart transplantation
You will not qualify if you...
- Declined informed consent
- Age < 18 years
- Receiving antileukocyte drugs
- Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
- Donation after circulatory death (DCD)
- Undergoing ex-vivo perfusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna
Vienna, State of Vienna, Austria, 1090
Actively Recruiting
Research Team
M
Martin H. Bernardi, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here